Brief: Neurogene Announces Upcoming Presentation Of Safety Data From Phase 1/2 Trial Of NGN-401 Gene Therapy

Neurogene

22/04/2024 21:45

April 22 (Reuters) - Neurogene Inc  NGNE.O :
    * NEUROGENE ANNOUNCES UPCOMING PRESENTATION OF SAFETY DATA
FROM
PHASE 1/2 TRIAL OF NGN-401 GENE THERAPY FOR RETT SYNDROME AT
ASGCT MEETING
    * NEUROGENE INC: NGN-401 HAS BEEN GENERALLY WELL-TOLERATED
BY
THREE PATIENTS WITH MULTIPLE MONTHS OF FOLLOW-UP
    * NEUROGENE INC: NGN-401 HAS BEEN GENERALLY WELL-TOLERATED
BY
THREE PATIENTS WITH MULTIPLE MONTHS OF FOLLOW-UP

Source text for Eikon:  ID:nBw27X0MQa 
Further company coverage:  NGNE.O 

 (Reuters.Briefs@thomsonreuters.com)